Evening update analysis for the EURUSD 23-09-2022
The EURUSD pair provided additional negative trades to succeed reaching our extended target at 0.9700, and the way seems open to achieve more decline in the upcoming period, to head towards 0.9620 areas as a next main station, noting that holding below 0.9805 represents initial condition to continue the bearish trend.
Fedex tries to recoup some losses - Analysis - 23-09-2022
Fedex Corporation's stock (FDX) rose in the last session after the company decided to raise shipping costs for land and air services and to cut costs, after withdrawing its full-year forecasts last year, triggering concerns about the company, with the stock now rising 0.84%, or 1.29 points, settling above 154.54, with trading volumes surpassing 10.2 million shares, above 10-day averages of 7.4 million shares.
Technically, the stock is trying to recoup some recent losses while venting off oversold saturation in the RSI, amid the dominance of the downward correctional short-term trend, with negative pressure from the 50-day SMA.
Therefore we expect the stock to return lower, targeting the support of 130.00, provided the current support of 158.40 held on.
Expected trend for today: Bearish
Salesforce rises through negative pressures - Analysis - 23-09-2022
SalesForce's stock (CRM) rose in the intraday levels after revealing a new profit target, with the stock rising 1.71% in the last session, or 2.52 points, settling at 150.15, with trading volumes surpassing 12.4 million shares, above 10-day averages of 7 million shares.
Technically, the stock is trying to recoup some recent losses amid negative pressure from the 50-day SMA, amid the dominance of the main downward short-term trend, with negative signals from the RSI after reaching overbought levels.
Therefore we expect the stock to return lower, targeting the support of 130.00, provided it settles below 154.73.
Expected trend for today: Bearish
Eli Lilly regains footing - Analysis - 23-09-2022
Eli Lilly and Company's stock (LLY) surged in the last session after the pharmaceutical company said there's a potential drug for diabetes from Mounjaro, might be the biggest drug at all, with expected profits of $25 billion a year, sending the stock 4.85% higher, or 14.39 points, settling at 310.87, with trading volumes surpassing 6 million shares, above 10-day averages of 2.7 million shares.
Technically, the main upward trend dominates in the medium and short terms, with positive signals from the RSI, while seeking a bottom to bounce it higher anew, leaning on the pivotal support of 296.50.
Therefore we expect more gains for the stock, targeting the pivotal resistance of 334.50, provided the support of 296.50 holds on.
Expected trend for today: Bullish